The novel mechanism of oxymatrine Affecting hERG currents at different temperatures

Cellular Physiology and Biochemistry

Volumn 26, Issue 4-5, 2010, Pages 513-522

  Hu, Mei Qin ^a   Dong, Zeng Xiang ^a   Zhao, Wen Xiao ^a   Sun, Jing ^a   Zhao, Xin ^a   Gu, Dong Fang ^a   Zhang, Yan ^a   Li, Bao Xin ^a   Yang, Bao Feng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

HEK293 cell; hERG channel; Oxymatrine; Patch clamp; Temperature

Indexed keywords

OXYMATRINE; POTASSIUM CHANNEL HERG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; KINETICS; LOW TEMPERATURE; PATCH CLAMP; PRIORITY JOURNAL; SOPHORA; TEMPERATURE; WHOLE CELL;

SOPHORA FLAVESCENS;

EID: 78149447464     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322319     Document Type: Article

References (37)

1. Sanguinetti MC, Tristani-Firouzi M: Herg potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
2. Tsujimae K, Suzuki S, Yamada M, Kurachi Y: Comparison of kinetic properties of quinidine and dofetilide block of herg channels. Eur J Pharmacol 2004;493:29-40.
3. Webster G, Berul CI: Congenital long-qt syndromes: A clinical and genetic update from infancy through adulthood. Trends Cardiovasc Med 2008;18:216-224.
4. Zunkler BJ: Human ether-a-go-go-related (herg) gene and atp-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 2006;112:12-37.
5. Ducroq J, Printemps R, Guilbot S, Gardette J, Salvetat C, Le Grand M: Action potential experiments complete herg assay and qt-interval measurements in cardiac preclinical studies. J Pharmacol Toxicol Methods 2007;56:159-170.
6. Shin WH, Kim KS, Kim EJ: Electrophysiological effects of brompheniramine on cardiac ion channels and action potential. Pharmacol Res 2006;54:414-420.
7. Danielsson BR, Lansdell K, Patmore L, Tomson T: Phenytoin and phenobarbital inhibit human herg potassium channels. Epilepsy Res 2003;55:147-157.
8. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W: Inhibition of herg k+ currents by antimalarial drugs in stably transfected hek293 cells. Eur J Pharmacol 2004;484:41-48.
9. Chapman H, Pasternack M: The action of the novel gastrointestinal prokinetic prucalopride on the herg k+ channel and the common t897 polymorph. Eur J Pharmacol 2007;554:98-105.
10. Ho JW, Ngan Hon PL, Chim WO: Effects of oxymatrine from ku shen on cancer cells. Anticancer Agents Med Chem 2009;9:823-826.
11. Hong-li S, Lei L, Lei S, Dan Z, De-li D, Guo-fen Q, Yan L, Wen-feng C, Bao-feng Y: Cardioprotective effects and underlying mechanisms of oxymatrine against ischemic myocardial injuries of rats. Phytot Res 2008;22:985-989.
12. Fan H, Li L, Zhang X, Liu Y, Yang C, Yang Y, Yin J: Oxymatrine downregulates tlr4, tlr2, myd88, and nf-kappab and protects rat brains against focal ischemia. Mediators Inflamm 2009;2009:704706.
13. Du X, Lu D, Daharsh ED, Yao A, Dewoody R, Yao J-A: Dimethyl sulfoxide effects on herg channels expressed in hek293 cells. J Pharmacol Toxicol Methods;54:164-172.
14. Gu DF, Li XL, Qi ZP, Shi SS, Hu MQ, Liu DM, She CB, Lv YJ, Li BX, Yang BF: Blockade of herg k+ channel by isoquinoline alkaloid neferine in the stable transfected hek293 cells. Naunyn Schmiedebergs Arch Pharmacol 2009;380:143-151.
15. Xiang X, Wang G, Cai X, Li Y: Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin Med J (Engl) 2002;115:593-596.
16. Chen XS, Wang GJ, Cai X, Yu HY, Hu YP: Inhibition of hepatitis b virus by oxymatrine in vivo. World J Gastroenterol 2001;7:49-52.
17. Chen Y, Li J, Zeng M, Lu L, Qu D, Mao Y, Fan Z, Hua J: the inhibitory effect of oxymatrine on hepatitis c virus in vitro. Zhonghua Gan Zang Bing Za Zhi 2001;9 Suppl:12-14.
18. Ma SC, Du J, But PP, Deng XL, Zhang YW, Ooi VE, Xu HX, Lee SH, Lee SF: Antiviral chinese medicinal herbs against respiratory syncytial virus. J Ethnopharmacol 2002;79:205-211.
19. Zou J, Ran ZH, Xu Q, Xiao SD: Experimental study of the killing effects of oxymatrine on human colon cancer cell line sw1116. Chin J Dig Dis 2005;6:15-20.
20. Song G, Luo Q, Qin J, Wang L, Shi Y, Sun C: Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B Biointerfaces 2006;48:1-5.
21. Zhang Y, Du J, Sun HL, Pan ZW, Lu YJ, Li BX, Yang BF: effects of matrine, oxymatrine and resveratrol on herg channel expression. Yao Xue Xue Bao 2007;42:139-144.
22. Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP: Human ether-a-go-go related gene (herg) k+ channels: Function and dysfunction. Prog Biophys Mol Biol 2008;98:137-148.
23. Sanguinetti MC, Curran ME, Spector PS, Keating MT: Spectrum of herg k+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci \USA 1996;93:2208-2212.
24. Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC: Long qt syndrome-associated mutations in the per-arnt-sim (pas) domain of herg potassium channels accelerate channel deactivation. J Biol Chem 1999;274:10113-10118.
25. Berecki G, Zegers JG, Verkerk AO, Bhuiyan ZA, de Jonge B, Veldkamp MW, Wilders R, van Ginneken AC: Herg channel (dys)function revealed by dynamic action potential clamp technique. Biophys J 2005;88:566-578.
26. Nakajima T, Furukawa T, Tanaka T, Katayama Y, Nagai R, Nakamura Y, Hiraoka M: Novel mechanism of herg current suppression in lqt2: Shift in voltage dependence of herg inactivation. Circ Res 1998;83:415-422.
27. Sasano T, Ueda K, Orikabe M, Hirano Y, Kawano S, Yasunami M, Isobe M, Kimura A, Hiraoka M: Novel c-terminus frameshift mutation, 1122fs/147, of herg in lqt2: Additional amino acids generated by frameshift cause accelerated inactivation. J Mol Cell Cardiol 2004;37:1205-1211.
28. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M: Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (ns1643). Mol Pharmacol 2006;69:266-277.
29. Hansen RS, Diness TG, Christ T, Wettwer E, Ravens U, Olesen SP, Grunnet M: Biophysical characterization of the new human ether-a-go-go-related gene channel opener ns3623 [n-(4-bromo-2-(1h-tetrazol-5-yl)-phenyl)-n'-(3'- trifluoromethylphenyl)urea[. Mol Pharmacol 2006;70:1319-1329.
30. Xu X, Recanatini M, Roberti M, Tseng GN: Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (ns1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1h-isoindol-5-ylamino]-nicotinic acid (pd307243). Mol Pharmacol 2008;73:1709-1721.
31. Grunnet M, Hansen RS, Olesen SP: Herg1 channel activators: A new anti-arrhythmic principle. Prog Biophys Mol Biol 2008;98:347-362.
32. Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D: Discovery of a small molecule activator of the human ether-a-go-go-related gene (herg) cardiac k+ channel. Mol Pharmacol 2005;67:827-836.
33. Perry M, Sachse FB, Sanguinetti MC: Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci \USA 2007;104:13827-13832.
34. Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X: Mallotoxin is a novel human ether-a-go-go-related gene (herg) potassium channel activator. J Pharmacol Exp Ther 2006;319:957-962.
35. Vandenberg JI, Varghese A, Lu Y, Bursill JA, Mahaut-Smith MP, Huang CL: Temperature dependence of human ether-a-go-go-related gene k+ currents. Am J Physiol Cell Physiol 2006;291:C165-175.
36. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long qt syndrome. Proc Natl Acad Sci \USA 2000;97:12329-12333.
37. Zhao XL, Gu DF, Qi ZP, Chen MH, Wei T, Li BX, Yang BF: Comparative effects of sophocarpine and sophoridine on herg k+ channel. Eur J Pharmacol 2009;607:15-22.